Institut Català de la Salut
Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), 28029 Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-04-25T13:40:22Z
2022-04-25T13:40:22Z
2021-08
Retinopatía diabética; Neurodegeneración; Unidad neurovascular
Retinopatia diabètica; Neurodegeneració; Unitat neurovascular
Diabetic retinopathy; Neurodegeneration; Neurovascular unit
The concept of diabetic retinopathy as a microvascular disease has evolved and is now considered a more complex diabetic complication in which neurovascular unit impairment plays an essential role and, therefore, can be considered as a main therapeutic target in the early stages of the disease. However, neurodegeneration is not always the apparent primary event in the natural story of diabetic retinopathy, and a phenotyping characterization is recommendable to identify those patients in whom neuroprotective treatment might be of benefit. In recent years, a myriad of treatments based on neuroprotection have been tested in experimental models, but more interestingly, there are drugs with a dual activity (neuroprotective and vasculotropic). In this review, the recent evidence concerning the therapeutic approaches targeting neurovascular unit impairment will be presented, along with a critical review of the scientific gaps and problems which remain to be overcome before our knowledge can be transferred to clinical practice.
This research was funded by grants from the Instituto de Salud Carlos III (DTS18/0163, PI19/01215, and ICI20/00129). The funders had no role in the design of the study; in the collection, analyses, or the interpretation of the data; in the writing of the manuscript, or in the decision to publish the results.
Article
Versió publicada
Anglès
Diabetis - Complicacions; Retinopatia diabètica - Tractament; DISEASES::Cardiovascular Diseases::Vascular Diseases::Diabetic Angiopathies::Diabetic Retinopathy; Other subheadings::Other subheadings::Other subheadings::/drug therapy; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Protective Agents::Neuroprotective Agents; ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::angiopatías diabéticas::retinopatía diabética; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::sustancias protectoras::fármacos neuroprotectores
MDPI
Pharmaceutics;13(8)
https://doi.org/10.3390/pharmaceutics13081320
info:eu-repo/grantAgreement/ES/PE2013-2016/DTS18%2F00163
info:eu-repo/grantAgreement/ES/PE2013-2016/PI19%2F01215
info:eu-repo/grantAgreement/ES/PE2013-2016/ICI20%2F00129
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]